Global Spread and Public Health Implications
According to Valneva, chikungunya began a rapid spread in 2004, having been identified in 110 countries across Asia, Africa, Europe, and the Americas. From 2013 to 2023, an estimated 3.7 million cases were reported in the Americas.1 According to the CDC, a total of 28 cases per year were reported in US citizens who recently returned from affected areas in Asia, Africa, or the Indian Ocean between 2006 and 2013. Local transmission was eventually identified, although no cases of local transmission have been reported since 2019. An estimated 60 million people living in the United States travel to countries in which mosquito-borne diseases such as chikungunya are endemic annually.2
As a result of climate change, the medical and economic burden of the virus is expected to grow due to mosquito vectors that transmit the disease spreading globally.1
“Considering the significant risk chikungunya poses to individuals living in or traveling to endemic areas, it’s crucial to ensure that the vaccine is accessible to people of all ages and capable of potentially offering long-term protection from a single shot,” continued Jaramillo, in the press release. “This is especially important in Low- and Middle-Income countries where access to vaccines is often limited.”
Next Steps for Pediatric Development
Moving forward, the results from the trial are expected to support a Phase III study in pediatric patients, which is expected to begin in the first quarter of next year. Ixchiq was first granted accelerated approval in November 2023 based on results from two studies in 3,500 individuals over 18 years of age with an increased risk of exposure to the virus in North America.1
References
1. Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®. Valneva. June 5, 2025. Accessed June 9, 2025. https://valneva.com/press-release/valneva-reports-positive-six-month-antibody-persistence-and-safety-phase-2-results-in-children-for-its-single-shot-chikungunya-vaccine-ixchiq/
2. FDA, CDC Recommend Pause on Valneva's Chikungunya Vaccine for Seniors. PharmExec. May 14, 2025. Accessed June 9, 2025. https://www.pharmexec.com/view/fda-cdc-recommend-pause-valneva-chikungunya-vaccine-seniors